Pathology: metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA);
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) | ||||
IMmotion-010, 2017 | CheckMate 914, 2017 | KEYNOTE-564, 0 | ||
pembrolizumab alone | 1 | T1 | ||
atezolizumab alone | 1 | T1 | ||
nivolumab alone | 1 | T1 | ||
placebo | 0 | T0 | T0 | |
nivolumab plus ipilimumab | 0 | T0 |